Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic hepatitis B
Biotech
AusperBio adds $120M series C to push hep B drug through ph. 3
AusperBio has raised $120 million to advance its oligonucleotide therapy for chronic hep B through phase 3 and hopefully on to commercialization.
Marissa Russo
Aug 28, 2026 10:26am
GSK hep B drug cures one-fifth of patients in ‘major step’
May 28, 2026 4:30am
Aligos sells China rights to HBV drug in $445M deal
Apr 16, 2026 9:12am
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
May 22, 2025 10:10am
Vir's hep B program fails to hit efficacy mark in phase 2
May 9, 2025 9:35am
